---
document_datetime: 2023-09-21 19:43:55
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_en.pdf
document_name: vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7098325
conversion_datetime: 2025-12-17 09:51:13.805816
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| EU Number        | (Invented) name   | Strength   | Pharmaceutical Form   | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                             |
|------------------|-------------------|------------|-----------------------|---------------------------|-----------------------|---------------------------|---------------------------------------|
| EU/1/18/1350/001 | Vantobra          | 170 mg     | Nebuliser solution    | Inhalation use            | ampoule (LDPE)        | 1.7 ml                    | 56 ampoules + 1 administration device |